Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Genfar

Sanofi reception

Poor Lantus sales sees Sanofi’s diabetes unit fall

French firm hit by insulin pricing pressures and soon faces biosimilar threat

Bristol-Myers Squibb (BMS) building

BMS shines in Q1, but Abilify generics cast a long shadow

Revenue up 6% but Ablify’s contribution likely to drop due to competition

- PMLiVE

Sanofi wins European approval for Lantus follow-up Toujeo

Long-acting insulin is a key part of the company's growth plans

Sanofi reception

Sanofi gains accelerated review for rare disease drug

New pill for Fabry disease could be approved by the FDA before the end of the year

- PMLiVE

Patient-centric strategies for emerging markets

Adopting an open and innovative mindset is key

Roche Basel Switzerland

Roche maintains top place in biologic sales

But the looming threat of biosimilars is set to shake up the market

- PMLiVE

Teva offers $40bn for Mylan as Perrigo backs away

Generic drug industry could be shaken up if deals go through

Making a difference with mobile health

Sanofi talks to PME about its latest mHealth initiative and tackling the diabetes epidemic

Daiichi Sankyo logo

Daiichi Sankyo offloads stake in India’s Sun Pharma

Japanese firm wants to shed its share of the generic Indian drugmaker

- PMLiVE

Rise of generics will curb France’s pharma growth

Generics are set to take a serious bite out of the market as a cash-strapped government pushes for cost controls

- PMLiVE

First generic version of Teva’s Copaxone cleared by FDA

Will be marketed as Glatopa by Momenta and Novartis’ Sandoz subsidiary

- PMLiVE

AstraZeneca and PatientsLikeMe team up on real-world data

Two groups hoping to harness the power of the patient forum network

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links